Open Up a World
WHERE ASTHMA CONTROL,
STEROID REDUCTION, AND
IMPROVED QUALITY OF LIFE ARE
POSSIBLE FOR CHILDREN

DUPIXENT demonstrated efficacy in key areas of asthma control in children aged 6-11 years.1,2

DUPIXENT is a
GINA‑recognized
treatment
option
for children with
asthma aged 6‑11
years
and has a
demonstrated
safety profile1‑3

DUPIXENT significantly
reduced severe
exacerbations in children
aged
6‑11 years1,2

Annualized rate of severe exacerbationsa through Week 52 in eosinophilic
phenotype (VOYAGE, primary endpoint)1

Weight-based dosing: DUPIXENT 100 mg Q2W (<30 kg) or 200 mg Q2W (≥30 kg).2

aSevere exacerbations were defined as deterioration of asthma requiring the use of systemic corticosteroids for at least 3 days or hospitalization or ED visit
due to asthma that required systemic corticosteroids.2

DUPIXENT sustained lung function improvement in children
aged 6‑11 years2

2X
improvement was seen with DUPIXENT at Week 12
in percent predicted pre-bronchodilator
FEV1 vs placebo (VOYAGE, key secondary endpoint)1
  • 5.21% improvement in percent predicted pre-bronchodilator FEV1 in children with EOS ≥150 cells/μL or FeNO ≥20 ppb (n=236)
    (eosinophilic phenotype) at Week 12 with DUPIXENT 100 mg/200 mg Q2W + SOC vs placebo + SOC (n=114)
  • 5.32% improvement in percent predicted pre-bronchodilator FEV1 in children with EOS ≥300 cells/μL (n=175) at Week 12 with
    DUPIXENT 100 mg/200 mg Q2W + SOC vs placebo + SOC (n=84)
3X
improvement was seen with DUPIXENT at Week 52
in percent predicted pre-bronchodilator
FEV1 vs placebo (VOYAGE, other secondary endpoint)1
  • 7.79% improvement in percent predicted pre-bronchodilator FEV1 in children with EOS ≥150 cells/μL or FeNO ≥20 ppb (n=236)
    (eosinophilic phenotype) at Week 52 with DUPIXENT 100 mg/200 mg Q2W + SOC vs placebo + SOC (n=114)
  • 8.35% improvement in percent predicted pre-bronchodilator FEV1 in children with EOS ≥300 cells/μL (n=175) at Week 52 with
    DUPIXENT 100 mg/200 mg Q2W + SOC vs placebo + SOC (n=84)

DUPIXENT reduced SCS use and improved asthma control in
children aged 6-11 years1

SCS reduction through Week 52 in eosinophilic phenotype
59%

EOS ≥150 cells/μL or
FeNO ≥20 ppb

Reduction in SCS courses with DUPIXENT 100 mg/200 mg Q2W + SOC (n=236) vs placebo + SOC (n=114) (adjusted annualized total SCS courses in all patients: 0.35 [95% CI: 0.26,0.48] vs 0.86 [95% CI: 0.62, 1.20]) (VOYAGE, other secondary endpoint)

66%

EOS ≥300 cells/µL

Reduction in SCS courses with DUPIXENT 100 mg/200 mg Q2W + SOC (n=175) vs placebo + SOC (n=84) (adjusted annualized total SCS courses in all patients: 0.27 [95% CI: 0.19, 0.40] vs 0.81 [95% CI: 0.56, 1.15]) (VOYAGE, other secondary endpoint)

LONG-TERM SCS USE MAY HAVE SIGNIFICANT SIDE EFFECTS IN CHILDREN4:
  • Lower height in adulthood
  • Gastrointestinal and cardiovascular complications
  • Increased susceptibility to infection
  • Behavioral changes

This is not an exhaustive list of all potential side effects associated with SCS.

DUPIXENT improved asthma control and quality of life in children

DUPIXENT IMPROVED
ASTHMA
CONTROL,
AS
MEASURED BY
ACQ-7-IA1,b

EOS ≥150 cells/μL or FeNO ≥20 ppb
(eosinophilic phenotype)

79% responder rate vs 69% responder rate in the placebo
group at Week 24 with DUPIXENT 100 mg/200 mg Q2W + SOC
(n=236) vs placebo + SOC (n=114) (OR: 1.82 [95% CI: 1.02,
3.24]) (other secondary endpoint)

EOS ≥300 cells/μL

81% responder rate vs 64% responder rate in the placebo
group at Week 24 with DUPIXENT 100 mg/200 mg Q2W + SOC
(n=175) vs placebo+ SOC (n=84) (OR: 2.79 [95% CI: 1.43, 5.44])
(other secondary endpoint)

Results are descriptive. Definitive conclusions cannot be made. Analysis of
change at Week 24 was not multiplicity controlled.

bA responder was defined as a patient with a reduction of ≥0.5 in
ACQ-7-IA score from baseline (minimal clinically important difference
for this outcome).1

ACQ-7-IA: Asthma Control Questionnaire, Interviewer Administered
version: Children 6-16 years respond to 6 questions about symptoms,
lung function, and medication use on a 7-point scale (0=no
impairment; 6=maximum impairment). Lower scores indicate better
asthma control. The minimal clinically important difference is 0.5.1,5

EOS ≥150 cells/μL or FeNO ≥20 ppb
(eosinophilic phenotype)

73% of children improved their quality of life at Week 24 with
DUPIXENT 100 mg/200 mg Q2W + SOC (n=211) vs 65% with placebo
+ SOC (n=107)

EOS ≥300 cells/μL

73% of children improved their quality of life at Week 24 with
DUPIXENT 100 mg/200 mg Q2W + SOC (n=158) vs 63% with placebo
+ SOC (n=81)

Results are descriptive. Definitive conclusions cannot be made. Analysis of
change at Week 24 was not multiplicity controlled.

cAnalysis of change at Week 24 was not multiplicity controlled; result is descriptive.1

PAQLQ(S)-IA: Pediatric Asthma Quality of Life Questionnaire With
Standardized Activities-Interviewer Administered: Children aged ≥7 to <12
years at randomization responded to questions about health-related quality of
life on a 7-point scale (7=no impairment; 1=severe impairment) at Weeks 12,
24, 36, and 52. The ability of DUPIXENT to impact health-related quality of life
was assessed by evaluating the LSM change in PAQLQ(S)-IA scores.1

ED, emergency department; EOS, eosinophils; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; GINA, Global Initiative for Asthma; LSM, least squares mean; OR, odds ratio; Q2W, once every 2 weeks; SCS, systemic corticosteroid; SOC, standard of care.

EXPLORE THE SAFETY DATA AND STUDY DESIGN FOR CHILDREN (6-11 YEARS)

VIEW safety data VIEW STUDY DESIGNS

Dosage and Administration
See the multiple dosage and administration options for patients on DUPIXENT.
EXPLORE ADMINISTRATION OPTIONS